Top 3 SEHK Growth Companies With High Insider Ownership In September 2024

In This Article:

As global markets face economic uncertainties, the Hong Kong market has not been immune to these fluctuations, with the Hang Seng Index recently experiencing a notable decline. Despite this backdrop, growth companies with high insider ownership often present unique opportunities for investors due to their potential for strong alignment between management and shareholder interests.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

Laopu Gold (SEHK:6181)

36.4%

34.7%

Akeso (SEHK:9926)

20.5%

54.7%

Fenbi (SEHK:2469)

31.2%

22.4%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.7%

69.8%

Pacific Textiles Holdings (SEHK:1382)

11.2%

37.7%

Zhejiang Leapmotor Technology (SEHK:9863)

14.7%

78.9%

DPC Dash (SEHK:1405)

38.2%

104.2%

Kindstar Globalgene Technology (SEHK:9960)

16.5%

88%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

109.2%

Beijing Airdoc Technology (SEHK:2251)

28.6%

93.4%

Click here to see the full list of 47 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

Kuaishou Technology

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kuaishou Technology is an investment holding company that offers live streaming, online marketing, and other services in the People’s Republic of China with a market cap of approximately HK$167.37 billion.

Operations: The company generates revenue primarily from its domestic operations (CN¥117.32 billion) and overseas activities (CN¥3.57 billion).

Insider Ownership: 19.4%

Kuaishou Technology, a growth company with high insider ownership, recently reported robust financial results for Q2 2024, with sales of CNY 30.98 billion and net income of CNY 3.98 billion. The company's earnings are forecast to grow at an annual rate of 18.8%, outpacing the Hong Kong market's average growth rate of 11.7%. Kuaishou's innovative AI initiatives, like Kling AI video generation model upgrades and new subscription programs, further strengthen its competitive edge in the digital content space.

SEHK:1024 Earnings and Revenue Growth as at Sep 2024
SEHK:1024 Earnings and Revenue Growth as at Sep 2024

Biocytogen Pharmaceuticals (Beijing)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a biotechnology company focused on the research and development of antibody-based drugs in China, the United States, and internationally, with a market cap of HK$2.41 billion.

Operations: The company's revenue segments include Gene Editing (CN¥75.50 million), Antibody Development (CN¥205.83 million), Animal Models Selling (CN¥354.44 million), and Pre-Clinical Pharmacology and Efficacy Evaluation (CN¥185.41 million).